Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

被引：6
|
作者：
Jaeger, Ulrich
Worel, Nina
McGuirk, Joseph
Riedell, Peter A.
Fleury, Isabelle
Borchmann, Peter
Du, Yan
Abdelhady, Ahmed M.
Han, Xia
Martinez-Prieto, Marcela
Waller, Edmund K.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA
[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Hop Maisonneuve Rosemont, Dept Med Specialisee, Hematooncol, Montreal, PQ, Canada
[5] Klinikum Univ Koln, Cologne, Germany
[6] Novartis Pharma AG, Shanghai, Peoples R China
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
[8] Emory Clin, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19537
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial.
    Jaeger, Ulrich
    Han, Xia
    Germano, Davide
    Quinn, David
    Gaddis, Dalia
    Masood, Aisha
    Mulvey, Tanya
    Mataraza, Jennifer
    Bishop, Michael R.
    Salles, Gilles
    Maziarz, Richard
    Schuster, Stephen
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Tisagenlecleucel and Lisocabtagene Maraleucel: Comparative Efficacy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Prieto, Marcela Martinez
    Bollu, Vamsi
    Kuzan, David
    Maziarz, Richard
    Kersten, Marie Jose
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S380 - S381
  • [43] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
  • [44] Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Karimi, Yasmin
    Abrisqueta, Pau
    de Vos, Sven
    Nijland, Marcel
    Offner, Fritz
    Osei-Bonsu, Kojo
    Rana, Ali
    Archer, Kimberly G.
    Song, Yaou
    Cordoba, Raul
    Falchi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
    Li, Yin
    Li, Chunfan
    Lv, Kebing
    Wang, Shixuan
    Li, Fei
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
  • [46] Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study
    Cavallo, Federica
    Follows, George A.
    Goy, Andre
    Vermaat, Joost
    Casasnovas, Rene-Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee M.
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian T.
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael W.
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros P.
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel A.
    Kalakonda, Nagesh
    BLOOD, 2019, 134
  • [47] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [48] Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial
    Jaeger, Ulrich
    Bishop, Michael R.
    Salles, Gilles
    Schuster, Stephen J.
    Maziarz, Richard T.
    Han, Xia
    Savchenko, Alexander
    Roscoe, Nathan
    Orlando, Elena
    Knoblock, Dawson
    Tiwari, Ranjan
    Pacaud, Lida Bubuteishvili
    Corradini, Paolo
    BLOOD, 2020, 136
  • [49] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Izquierdo, Antonia Rodriguez
    Martin, Eva Maria Donato
    Garcia-Sancho, Alejandro Martin
    Sandoval-Sus, Jose David
    Tilly, Herve
    Vandenberghe, Elizabeth
    Hirata, Jamie
    Choudhry, Priya
    Chang, Yi Meng
    Musick, Lisa
    McMillan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Vukcevic, Mirko
    Yung, Mallory
    Khan, Mali
    Houpt, Bethany
    Schnell, Frederick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
12345